A phase I clinical trial aims at investigating the efficacy of the expression of the tumor necrosis factor (TNF-α) in cutaneous metastases of malignant melanoma after the intratumoral jet injection of the MIDGE gene carrier. This evidence concerns the gene TNF and melanoma.